Engineered anti-il-23r antibodies
AssigneeSchering Corporation
InventorLeonard G. Presta
Life of this patent
Estimating the term…
Abstract
Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Claims36
A binding compound that binds to human IL-23R comprising:
- a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs:
- 26-40 and 52;
- and
- b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs:
- 11-25.
2-6. (canceled)
8-9. (canceled)
11-12. (canceled)
A binding compound that binds to human IL-23R, comprising:
- a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
- CDRL1 comprises the sequence of SEQ ID NO:
- 29 or 52 or a variant thereof;
- CDRL2 comprises the sequence of SEQ ID NO:
- 34 or a variant thereof;
- and
- CDRL3 comprises the sequence of SEQ ID NO:
- 39 or a variant thereof;
- and
- b) a heavy chain variable domain, or antigen binding fragment thereof, comprising
- CDRH1, CDRH2 and CDRH3, wherein:
- CDRH1 comprises the sequence of SEQ ID NO:
- 14 or a variant thereof;
- CDRH2 comprises the sequence of SEQ ID NO:
- 19 or a variant thereof;
- and
- CDRH3 comprises the sequence of SEQ ID NO:
- 24 or a variant thereof;
- wherein each variant comprises up to five conservatively modified amino acid substitutions.
15-16. (canceled)
A binding compound that binds to human IL-23R comprising:
- a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
- CDRL1 comprises the sequence of SEQ ID NO:
- 29 or 52;
- CDRL2 comprises the sequence of SEQ ID NO:
- 34;
- and
- CDRL3 comprises the sequence of SEQ ID NO:
- 39;
- and
- b) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
- CDRH1 comprises the sequence of SEQ ID NO:
- 14;
- CDRH2 comprises the sequence of SEQ ID NO:
- 19;
- and
- CDRH3 comprises the sequence of SEQ ID NO:
- 24;
18-19. (canceled)
A binding compound that binds to human IL-23R, comprising:
- a) an antibody light chain variable domain, or antigen binding fragment thereof, consisting essentially of a sequence selected from the group consisting of SEQ ID NOs:
- 48, 49 and 53;
- and
- b) an antibody heavy chain variable domain, or antigen binding fragment thereof, consisting essentially of a sequence selected from the group consisting of SEQ ID NOs:
- 45, 46 and 47.
(canceled)
An antibody, or antigen binding fragment thereof, that is able to block the binding of a binding compound comprising:
- a) an antibody light chain variable domain comprising the sequence of SEQ ID NO:
- 54;
- and
- b) an antibody heavy chain variable domain comprising the sequence of SEQ ID NO:
- 50,
- to human IL-23R in a cross-blocking assay.
(canceled)
(canceled)
An antibody, or antigen binding fragment thereof, that is able to block binding of human IL-23R to the antibody deposited with ATCC under accession number PTA-7800 in a cross-blocking assay.
An antibody, or antigen binding fragment thereof, that is able to block binding of human IL-23R to the antibody deposited with ATCC under accession number PTA-7801 in a cross-blocking assay.
A binding compound that binds to human IL-23R, comprising:
- a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO:
- 58;
- and
- b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO:
- 57.
Dependencies are inferred from the claim text.